Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Sci Total Environ ; 954: 176506, 2024 Sep 26.
Artículo en Inglés | MEDLINE | ID: mdl-39341242

RESUMEN

BACKGROUND: Fine particulate matter (PM2.5) pollution and extreme temperature events (ETEs) are main environmental threats to human health. Elevated stroke mortality has been growingly linked to PM2.5 mass exposure, while its relationship with PM2.5 constituents was extensively unstudied across the globe. Additionally, no prior assessments have investigated the interactive effects of PM2.5 constituents and ETEs on stroke mortality. METHODS: Province-wide records of 320,372 stroke deaths collected in eastern China during 2016-2019 were analyzed using an individual-level time-stratified case-crossover design. Daily gridded estimates of PM2.5 mass and its major constituents (i.e., black carbon [BC], organic matter [OM], ammonium [NH4+], sulfate [SO42-], and nitrate [NO3-]) were assigned to stroke cases on case days and control days at the residential address. We assessed 12 ETEs defined by multiple combinations of air temperature thresholds (2.5-10th percentiles for cold spell, 90-97.5th percentiles for heat wave) and durations (2-4 days). Conditional logistic regression model was applied to investigate associations of short-term exposure to PM2.5 constituents and ETEs with stroke mortality. Odds ratio and its 95% confidence interval (CI) were assessed for an interquartile range (IQR) increase in each PM2.5 constituent and on ETEs days compared with non-ETEs days. Additive interactive effects were quantitatively evaluated via relative excess odds due to interaction (REOI), attributable proportion due to interaction (AP), and synergy index (SI). RESULTS: Elevated overall stroke mortality was significantly related to PM2.5 constituents, with the largest odds observed for NO3- (1.04, 95% CI: 1.03-1.04, IQR = 11.25 µg/m3), followed by OM (1.03, 1.03-1.04, IQR = 7.97 µg/m3), NH4+ (1.03, 1.02-1.04, IQR = 6.66 µg/m3), BC (1.03, 1.02-1.03, IQR = 1.41 µg/m3), and SO42- (1.03, 1.02-1.03, IQR = 6.67 µg/m3). Overall, higher risks of stroke mortality were identified in analyses using more rigorous thresholds and lengthened durations of ETEs definitions, ranging from 1.19 (1.17-1.21) to 1.55 (1.51-1.60) for heat wave, and 1.03 (1.02-1.05) to 1.11 (1.08-1.15) for cold spell, respectively. We observed consistent evidence for the synergistic effects of heat wave and PM2.5 constituents on both ischemic and hemorrhagic stroke mortality, where compound exposures to heat wave and secondary inorganic aerosols (i.e., NO3-, SO42-, and NH4+) posed greater increases in risk (0.23< REOI <0.81, 0.16< AP <0.39, and 2.63< SI <8.19). CONCLUSIONS: Short-term exposure to both PM2.5 constituents and ETEs were associated with heightened stroke mortality, and heat wave may interact synergistically with PM2.5 constituents to trigger stroke deaths.

2.
BMJ Open ; 14(4): e074188, 2024 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-38684278

RESUMEN

OBJECTIVES: To compare the efficacy and safety of seven Chinese patent medicines (CPMs) combined with conventional triple/quadruple therapy (T/Q) for Helicobacter pylori-positive peptic ulcers. DESIGN: A systematic review and network meta-analysis. DATA SOURCES: China National Knowledge Infrastructure, VIP database, Wanfang database, ScienceDirect, EBSCO, EMBASE, Web of Science, Cochrane Library and PubMed were searched through 1 June 2022. ELIGIBILITY CRITERIA: Randomised controlled trials (RCTs) testing CPMs combined with T/Q for H. pylori-positive peptic ulcers were included. The CPMs included Anweiyang capsule, Jianweiyuyang tablets/capsule/granule, Jinghuaweikang capsule, Kangfuxin liquid, Puyuanhewei capsule, Weifuchun tablets/capsule and Weisu granule. At least one of the following outcome indicators was recorded: complete ulcer healing rate (CUHR), effective rate (ER), H. pylori eradication rate (HPER), rate of peptic ulcer recurrence (RPUR) and incidence of adverse reactions (IAR). DATA EXTRACTION AND SYNTHESIS: Two researchers independently conducted the study selection and extracted data for included studies. The risk of bias was assessed using the Cochrane risk of bias tool. A pairwise meta-analysis was performed using RevMan V.5.3. Network meta-analysis was performed using STATA/MP V.15.0. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation. RESULTS: A total of 36 RCTs involving 3620 patients were included. Compared with T/Q alone, Weisu+T/Q, Weifuchun+T/Q and Puyuanhewei+T/Q had the highest CUHR, ER and HPER, respectively. Weisu+T/Q and Jianweiyuyang+T/Q had the lowest RPUR and IAR, respectively. The cluster analysis results showed Jianweiyuyang+T/Q might be the best choice concerning efficacy and safety simultaneously, followed by Kangfuxin+T/Q. CONCLUSION: Among the combination therapies with the CPMs, Jianweiyuyang+T/Q might be the most favourable option for H. pylori-positive peptic ulcers, followed by Kangfuxin+T/Q. Considering the limited quantity and quality of the included RCTs, the results should be interpreted with caution. PROSPERO REGISTRATION NUMBER: CRD42022327687.


Asunto(s)
Antibacterianos , Quimioterapia Combinada , Medicamentos Herbarios Chinos , Infecciones por Helicobacter , Helicobacter pylori , Metaanálisis en Red , Úlcera Péptica , Humanos , Infecciones por Helicobacter/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Medicamentos Herbarios Chinos/efectos adversos , Úlcera Péptica/tratamiento farmacológico , Úlcera Péptica/microbiología , Antibacterianos/uso terapéutico , Antibacterianos/efectos adversos , Antibacterianos/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Inhibidores de la Bomba de Protones/uso terapéutico , Inhibidores de la Bomba de Protones/administración & dosificación , Inhibidores de la Bomba de Protones/efectos adversos , Antiulcerosos/uso terapéutico , Antiulcerosos/administración & dosificación , Antiulcerosos/efectos adversos , Resultado del Tratamiento , Medicamentos sin Prescripción/uso terapéutico , Medicamentos sin Prescripción/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA